Source comparison
MK-677 Perimenopause Research: Comparison of Key Trials
Chapman et al. (2015, JBMR) 65 postmenopausal women, ages 60–81 25 mg daily 12 months Lumbar spine BMD +4.3% vs +0.8% placebo Increased appetite (68%), mild edema (22%), fasting glucose +8 mg/dL Murphy et al. (2018, JCEM) 42 postmenopausal women, ages 55–70 24
This comparison does not assign a generated winner or score.
- Chapman et al. (2015, JBMR)
- 65 postmenopausal women, ages 60–81
- 25 mg daily
- 12 months
- Lumbar spine BMD
- +4.3% vs +0.8% placebo
- Increased appetite (68%), mild edema (22%), fasting glucose +8 mg/dL
- Murphy et al. (2018, JCEM)
- 42 postmenopausal women, ages 55–70
- 24 months
- Lean body mass
- +2.1 kg vs +0.3 kg placebo
- No serious adverse events, transient joint stiffness (15%)
- Stanford Pilot (2024, unpublished)
- 18 perimenopausal women, ages 47–53
- 6 months
- IGF-1 response by estradiol level
- 32% increase (high E2) vs 67% increase (low E2)
- Appetite increase (72%), no glucose or lipid changes
- Clemmons et al. (2012, Endocrinology)
- 38 postmenopausal women, ages 58–75
- 10 mg vs 25 mg daily
- Dose-response curve for BMD
- 10 mg: +2.1%, 25 mg: +4.8%
- Dose-dependent appetite and edema incidence